RxDoctor Payments Data

Elva Canales

Family · Laredo, TXNPI 1558762328

Payments from drug & device makers

$2,270in general payments, 2019–2025

Across 88 payments — averaging $25.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$637
  • AstraZeneca$365
  • Novo Nordisk$303
  • Amgen$223
  • Bayer$125
  • Esperion Therapeutics, Inc.$108
  • plus $510 from 12 others

What the payments were for

  • Food & beverage$2,18596%
  • Education$854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,270 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$14,649
Medicare patients
59
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide15$17,157
OzempicSemaglutide13$16,208
MounjaroTirzepatide12$14,460
Gabapentin26$409
Atorvastatin Calcium54$301
Pioglitazone-MetforminPioglitazone Hcl/Metformin Hcl14$297
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$280
Albuterol Sulfate HfaAlbuterol Sulfate11$270
Ezetimibe14$244
Metformin Hcl30$225
Rosuvastatin Calcium37$222
Losartan Potassium34$218
Montelukast Sodium20$218
Levothyroxine Sodium20$208
Pantoprazole Sodium36$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$637$31,61627 claims
Novo NordiskOzempic$303$16,20813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →